Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties
View Full Paper
Ask AI
Bookmark
Share
Why the study?
Does eicosapentaenoic acid and its triene prostaglandin derivatives prevent platelet aggregation in human platelet-rich plasma?
Population
In vitro models including human platelet-rich plasma, washed platelets, bovine aorta microsomes…
Comparison
Eicosapentaenoic acid and its triene… vs Arachidonic acid and its diene prostaglandin…
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
May explain EPA antithrombotic effects in vitro; hypothesis-generating and leaves open human efficacy trials.
Structured PICO
Does eicosapentaenoic acid and its triene prostaglandin derivatives prevent platelet aggregation in human platelet-rich plasma?
P
Population
In vitro models including human platelet-rich plasma (PRP), washed platelets, bovine aorta microsomes, aspirin-treated platelet microsomes, bovine coronary artery, and rabbit thoracic aorta
I
Intervention
Eicosapentaenoic acid and its triene prostaglandin derivatives (PGH3, thromboxane A3, PGI3)
C
Comparator
Arachidonic acid and its diene prostaglandin derivatives (PGH2, thromboxane A2, PGI2)
O
Outcome
Platelet aggregation, ADP release, cyclic AMP levels, and vascular smooth muscle tonesurrogate
Triene prostaglandins derived from eicosapentaenoic acid inhibit platelet aggregation and increase cyclic AMP, providing a biochemical mechanism for the antithrombotic effects of eicosapentaenoic acid.
Cite This Study
Needleman et al. (1979) studied this question.
View Full Paper
Ask AI
Bookmark
Share